Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.56
CELG's Cash-to-Debt is ranked lower than
86% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. CELG: 0.56 )
Ranked among companies with meaningful Cash-to-Debt only.
CELG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.36  Med: 1.84 Max: No Debt
Current: 0.56
Equity-to-Asset 0.24
CELG's Equity-to-Asset is ranked lower than
86% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CELG: 0.24 )
Ranked among companies with meaningful Equity-to-Asset only.
CELG' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.3  Med: 0.53 Max: 0.88
Current: 0.24
-0.3
0.88
Interest Coverage 6.33
CELG's Interest Coverage is ranked lower than
89% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 6.33 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s Interest Coverage Range Over the Past 10 Years
Min: 6.33  Med: 27.63 Max: 428.04
Current: 6.33
6.33
428.04
Piotroski F-Score: 6
Altman Z-Score: 4.21
Beneish M-Score: -2.65
WACC vs ROIC
12.41%
19.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 28.20
CELG's Operating Margin % is ranked higher than
91% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. CELG: 28.20 )
Ranked among companies with meaningful Operating Margin % only.
CELG' s Operating Margin % Range Over the Past 10 Years
Min: -64.94  Med: 29 Max: 32.84
Current: 28.2
-64.94
32.84
Net Margin % 17.80
CELG's Net Margin % is ranked higher than
87% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. CELG: 17.80 )
Ranked among companies with meaningful Net Margin % only.
CELG' s Net Margin % Range Over the Past 10 Years
Min: -68.02  Med: 23.31 Max: 28.88
Current: 17.8
-68.02
28.88
ROE % 34.72
CELG's ROE % is ranked higher than
96% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. CELG: 34.72 )
Ranked among companies with meaningful ROE % only.
CELG' s ROE % Range Over the Past 10 Years
Min: -48.42  Med: 24.32 Max: 34.72
Current: 34.72
-48.42
34.72
ROA % 7.44
CELG's ROA % is ranked higher than
88% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. CELG: 7.44 )
Ranked among companies with meaningful ROA % only.
CELG' s ROA % Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 7.44
-38.07
15.8
ROC (Joel Greenblatt) % 183.43
CELG's ROC (Joel Greenblatt) % is ranked higher than
96% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. CELG: 183.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CELG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -421.4  Med: 179.18 Max: 212.3
Current: 183.43
-421.4
212.3
3-Year Revenue Growth Rate 22.80
CELG's 3-Year Revenue Growth Rate is ranked higher than
75% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CELG: 22.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CELG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 20.6  Med: 37.6 Max: 241.3
Current: 22.8
20.6
241.3
3-Year EBITDA Growth Rate 19.30
CELG's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. CELG: 19.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CELG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34  Med: 26.6 Max: 295.8
Current: 19.3
-34
295.8
3-Year EPS without NRI Growth Rate 14.00
CELG's 3-Year EPS without NRI Growth Rate is ranked higher than
70% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. CELG: 14.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CELG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.8  Med: 23.55 Max: 109.7
Current: 14
-60.8
109.7
GuruFocus has detected 2 Warning Signs with Celgene Corp $CELG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CELG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CELG Guru Trades in Q1 2016

Ray Dalio 4,100 sh (New)
Julian Robertson 228,840 sh (New)
Joel Greenblatt 68,917 sh (New)
Lee Ainslie 4,900 sh (+105.88%)
Pioneer Investments 3,821,415 sh (+3.96%)
Murray Stahl 8,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 256,000 sh (unchged)
Mairs and Power Sold Out
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Mario Gabelli 27,144 sh (-7.26%)
RS Investment Management 111,048 sh (-14.12%)
Ken Fisher 198,160 sh (-19.27%)
» More
Q2 2016

CELG Guru Trades in Q2 2016

Ronald Muhlenkamp 19,809 sh (New)
Ken Heebner 20,000 sh (New)
Jim Simons 563,038 sh (New)
Steven Cohen 21,200 sh (New)
Joel Greenblatt 317,274 sh (+360.37%)
Ray Dalio 7,300 sh (+78.05%)
Julian Robertson 379,140 sh (+65.68%)
RS Investment Management 141,861 sh (+27.75%)
Pioneer Investments 4,222,301 sh (+10.49%)
Ken Fisher 204,128 sh (+3.01%)
Murray Stahl 8,000 sh (unchged)
Lee Ainslie Sold Out
Mario Gabelli 26,988 sh (-0.57%)
Eaton Vance Worldwide Health Sciences Fund 139,500 sh (-45.51%)
» More
Q3 2016

CELG Guru Trades in Q3 2016

Paul Tudor Jones 2,500 sh (New)
Signature Select Canadian Fund 34,700 sh (New)
Steven Cohen 249,800 sh (+1078.30%)
Ray Dalio 35,700 sh (+389.04%)
Ronald Muhlenkamp 73,515 sh (+271.12%)
Jim Simons 1,225,638 sh (+117.68%)
Pioneer Investments 4,595,046 sh (+8.83%)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (+218.94%)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 8,000 sh (unchged)
Ken Heebner Sold Out
Ken Fisher 199,770 sh (-2.13%)
Julian Robertson 368,940 sh (-2.69%)
Joel Greenblatt 268,338 sh (-15.42%)
Mario Gabelli 15,888 sh (-41.13%)
» More
Q4 2016

CELG Guru Trades in Q4 2016

George Soros 3,500 sh (New)
Steven Cohen 646,900 sh (+158.97%)
Ken Fisher 203,488 sh (+1.86%)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 8,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (unchged)
Ray Dalio Sold Out
Ronald Muhlenkamp 72,688 sh (-1.12%)
Pioneer Investments 4,520,555 sh (-1.62%)
Paul Tudor Jones 2,100 sh (-16.00%)
Julian Robertson 298,740 sh (-19.03%)
Mario Gabelli 11,339 sh (-28.63%)
Jim Simons 751,338 sh (-38.70%)
Joel Greenblatt 119,987 sh (-55.29%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:GILD, NYSE:NVO, NAS:BIIB, OTCPK:SHPGF, NAS:AMGN, OTCPK:CSLLY, NAS:REGN, NAS:ALXN, OTCPK:ALIOY, NAS:INCY, NAS:VRTX, OTCPK:GIKLY, NAS:BMRN, OTCPK:UCBJY, OTCPK:GMXAY, OTCPK:NVZMF, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:UTHR » details
Traded in other countries:CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Celgene Corp is incorporated in Delaware in 1986. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST, IMNOVID, THALOMID (inclusive of Thalidomide Celgene, ISTODAX and azacitidine for injection (generic version of VIDAZA). It owns and operates a manufacturing facility in Zofingen, Switzerland which produces the active pharmaceutical ingredient (API) for REVLIMID and THALOMID and have contracted with third-party contract manufacturers to provide backup API manufacturing services for these products. Manufacturing services for REVLIMID and THALOMID, which consist of formulation, encapsulation, packaging, warehousing and distribution, are performed at our drug product manufacturing facility in Boudry, Switzerland. The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.

Top Ranked Articles about Celgene Corp

Gilead and Celgene Among Biotechnology Stocks to Buy Industry contains at least 2 stocks that gurus are adding to their portfolios
The general biotechnology industry offers gurus many opportunities to increase their portfolio returns. Several biotech stocks, including Gilead Sciences Inc. (NASDAQ:GILD) and Celgene Corp. (NASDAQ:CELG), have positive financial outlooks. Read more...

Ratios

vs
industry
vs
history
PE Ratio 47.48
CELG's PE Ratio is ranked lower than
69% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. CELG: 47.48 )
Ranked among companies with meaningful PE Ratio only.
CELG' s PE Ratio Range Over the Past 10 Years
Min: 17.92  Med: 46.38 Max: 603.25
Current: 47.48
17.92
603.25
Forward PE Ratio 16.50
CELG's Forward PE Ratio is ranked higher than
64% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. CELG: 16.50 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 47.48
CELG's PE Ratio without NRI is ranked lower than
69% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. CELG: 47.48 )
Ranked among companies with meaningful PE Ratio without NRI only.
CELG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.82  Med: 46.24 Max: 482.6
Current: 47.48
17.82
482.6
Price-to-Owner-Earnings 37.31
CELG's Price-to-Owner-Earnings is ranked lower than
58% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. CELG: 37.31 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CELG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.44  Med: 40.26 Max: 1163.68
Current: 37.31
15.44
1163.68
PB Ratio 13.92
CELG's PB Ratio is ranked lower than
91% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. CELG: 13.92 )
Ranked among companies with meaningful PB Ratio only.
CELG' s PB Ratio Range Over the Past 10 Years
Min: 4.02  Med: 9.4 Max: 23.65
Current: 13.92
4.02
23.65
PS Ratio 8.46
CELG's PS Ratio is ranked higher than
61% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. CELG: 8.46 )
Ranked among companies with meaningful PS Ratio only.
CELG' s PS Ratio Range Over the Past 10 Years
Min: 5.41  Med: 9.89 Max: 27.81
Current: 8.46
5.41
27.81
Price-to-Free-Cash-Flow 25.37
CELG's Price-to-Free-Cash-Flow is ranked lower than
56% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. CELG: 25.37 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CELG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.96  Med: 33.46 Max: 2438.33
Current: 25.37
14.96
2438.33
Price-to-Operating-Cash-Flow 23.95
CELG's Price-to-Operating-Cash-Flow is ranked lower than
56% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. CELG: 23.95 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CELG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.93  Med: 31.47 Max: 1279.09
Current: 23.95
13.93
1279.09
EV-to-EBIT 34.21
CELG's EV-to-EBIT is ranked lower than
69% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. CELG: 34.21 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.6  Med: 33.9 Max: 156.6
Current: 34.21
-28.6
156.6
EV-to-EBITDA 28.68
CELG's EV-to-EBITDA is ranked lower than
68% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. CELG: 28.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.4  Med: 28.5 Max: 132.5
Current: 28.68
-31.4
132.5
PEG Ratio 3.02
CELG's PEG Ratio is ranked lower than
59% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. CELG: 3.02 )
Ranked among companies with meaningful PEG Ratio only.
CELG' s PEG Ratio Range Over the Past 10 Years
Min: 1.38  Med: 2.33 Max: 3.26
Current: 3.02
1.38
3.26
Shiller PE Ratio 98.03
CELG's Shiller PE Ratio is ranked lower than
73% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. CELG: 98.03 )
Ranked among companies with meaningful Shiller PE Ratio only.
CELG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 84.46  Med: 143.33 Max: 3211
Current: 98.03
84.46
3211
Current Ratio 3.67
CELG's Current Ratio is ranked lower than
54% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CELG: 3.67 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 5.7 Max: 11.23
Current: 3.67
1.35
11.23
Quick Ratio 3.50
CELG's Quick Ratio is ranked lower than
54% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. CELG: 3.50 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 5.52 Max: 11.11
Current: 3.5
1.13
11.11
Days Inventory 401.70
CELG's Days Inventory is ranked lower than
91% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CELG: 401.70 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 104.34  Med: 244.42 Max: 401.7
Current: 401.7
104.34
401.7
Days Sales Outstanding 52.68
CELG's Days Sales Outstanding is ranked higher than
58% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. CELG: 52.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.42  Med: 57.78 Max: 71.27
Current: 52.68
43.42
71.27
Days Payable 205.92
CELG's Days Payable is ranked higher than
85% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. CELG: 205.92 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 139.99 Max: 209.22
Current: 205.92
61.81
209.22

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.80
CELG's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CELG: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CELG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17  Med: -3.2 Max: 4.5
Current: 1.8
-17
4.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.35
CELG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
60% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. CELG: 2.35 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CELG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.8  Med: 4.55 Max: 39.9
Current: 2.35
1.8
39.9
Price-to-Median-PS-Value 0.86
CELG's Price-to-Median-PS-Value is ranked higher than
60% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. CELG: 0.86 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CELG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.24 Max: 8.75
Current: 0.86
0.64
8.75
Price-to-Peter-Lynch-Fair-Value 2.87
CELG's Price-to-Peter-Lynch-Fair-Value is ranked lower than
68% of the 72 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. CELG: 2.87 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CELG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.46  Med: 2 Max: 5.1
Current: 2.87
0.46
5.1
Earnings Yield (Greenblatt) % 2.93
CELG's Earnings Yield (Greenblatt) % is ranked higher than
83% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. CELG: 2.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CELG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.6  Med: 2.8 Max: 6.7
Current: 2.93
0.6
6.7
Forward Rate of Return (Yacktman) % 18.95
CELG's Forward Rate of Return (Yacktman) % is ranked higher than
54% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 15.82 vs. CELG: 18.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CELG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.1  Med: 2.1 Max: 34.8
Current: 18.95
0.1
34.8

More Statistics

Revenue (TTM) (Mil) $11,229
EPS (TTM) $ 2.49
Beta1.52
Short Percentage of Float0.96%
52-Week Range $94.39 - 127.00
Shares Outstanding (Mil)777.97

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 13,284 15,316 18,576
EPS ($) 6.52 7.61 8.75
EPS without NRI ($) 6.52 7.61 8.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
22.10%
Dividends per Share ($)
» More Articles for NAS:CELG

Headlines

Articles On GuruFocus.com
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Feb 14 2017 
Celgene Switzerland Invests in Jounce Therapeutics Feb 02 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Jan 24 2017 
9 Stocks Ray Dalio Continues to Buy Dec 22 2016 
When Is the PEG Ratio Superior to the P/E Ratio? Part 2 Nov 03 2016 
Abbott Develops AML Tests With Celgene and Agios Oct 13 2016 
Celgene: Is It a Buy? Jun 21 2016 
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
Gilead and Celgene Among Biotechnology Stocks to Buy May 26 2016 
DISH Network, H&R Block, Celgene, Plum Creek Timber Log Largest Insider Sells Jan 04 2016 

More From Other Websites
5:47 am Celgene receives EC approval for new indication for REVLIMID Feb 25 2017
Emergent (EBS) Beats Earnings, Revenue Estimates in Q4 Feb 24 2017
Is There More Than Meets the Eye on Celgene’s President, COO Retirement? Feb 24 2017
REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance... Feb 24 2017
REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance... Feb 24 2017
CELGENE CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Feb 23 2017
Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and... Feb 23 2017
Celgene’s Revlimid Secures Label Expansion Feb 23 2017
FDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with... Feb 22 2017
Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising Feb 22 2017
Blog Coverage Celgene's Multiple Sclerosis Drug Reported Positive Phase-III Results Feb 21 2017
Celgene MS Drug Reports Positive Phase 3 Data Feb 20 2017
Forget Alexion, Buy these 4 Biotech Stocks Instead Feb 20 2017
Celgene MS Drug Wins In Trial; Will Safety Top Novartis, Biogen? Feb 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)